Is the trend a friend…or the enemy? Two recent Wall Street Journal articles paint a scary picture when read together, one shining a light on everything wrong with how we approach diet and metabolic health in this country.
The first announces that Ozempic and its GLP-1 cousins are on track to become an everything-drug — heart disease, kidney disease, liver disease, sleep apnea, arthritis, even Alzheimer’s. Researchers are floating the idea that a majority of American adults could eventually be “eligible.” One pharma blogger put it well: it’s getting hard to find something GLP-1s aren’t good for. (“Ozempic for Everyone? Doctors Hail ‘GLP-1s,'” The Wall Street Journal, May 25, 2026)
GLP-1 – The Hidden Cost
The second piece, run the same week, is the quiet correction: people on these drugs are losing muscle along with fat — up to 10% of lean mass, comparable to a decade or more of aging. Doctors are calling frailty a hidden cost of the weight-loss boom. Patients describe feeling cold from the inside, too weak to open a jar, sidelined from basic tasks. One doctor’s line stuck with me: “We are curing obesity by encouraging frailty.” (“Frailty Is a Hidden Cost of Weight-Loss Drugs,” The Wall Street Journal, May 26, 2026)**
And what’s the proposed fix for that? Special diets. More monitoring. More pharma-adjacent intervention layered on top of the first intervention.
I’ll pass.
If the answer to “this drug is causing malnutrition” is “let’s manage the malnutrition,” we’ve stopped asking the actual question, which is: why are 100 million American adults metabolically broken enough to need a drug like this in the first place?
Shaping Nutrition Behaviors in Children
We already run two massive nutrition programs in this country — school lunch and SNAP — and we’ve let both of them become delivery systems for sugar water and chemically engineered Franken-foods. Designed to taste great, and program your metabolism so you won’t “eat just one”.
This is not feeding kids and families; we’re training their palates, and literally shaping addictive behaviors toward the exact outcomes that later get treated with a $1,000-a-month injection. It’s not a coincidence, it’s a pipeline. We subsidize the front end of the disease and then subsidize the back end of the “cure,” and somehow the actual problem never gets fixed.
Is the next decade’s step spending more billions figuring out how to keep people from wasting away on a drug that’s masked the underlying problem? Starting now, maybe subsidize healthy food and habits. Real protein, real produce, real meals — in school lunches, in SNAP, in the institutions that are shaping eating behavior at scale, especially for kids who don’t get a say in what’s in front of them. Fix the input. You won’t need nearly as much of the output.
Profits Over Health
It’s not a quick fix, but we’re in a negative spiral that getting worse. GLP-1s have a place — for people with true metabolic disease, used deliberately, alongside exercise and real nutrition, they’re a legitimate tool. But marketing drugs as the inevitable answer for over a third of the country— or more — while the high-fructose corn syrup and other subsidized foods increasingly manufactures the demand, isn’t medicine. It’s a business model. One that is certainly legal…but it’s also not right.
We don’t need a prescription pill for every American. We need a plate.
GLP-1 medications have transformed the conversation around weight loss—but they’re not the whole story. GLP-1 Explained: The Good, the Bad, and What No One Tells You offers a balanced, easy-to-understand look at how these medications work, their potential benefits, common side effects, and the important questions to consider before starting treatment.
Affiliate Disclosure: We may earn a small commission from qualifying purchases at no additional cost to you.
Related Articles: